

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel as Chief Scientific Advisor



A seasoned pharmaceutical industry executive with over 40 years at the forefront of innovation, including at Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel MIRA Pharmaceuticals' mission to tackle unmet needs in neurologic and neuropsychiatric disorders

MIRA Pharmaceuticals Inc., an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.

Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA. He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career. Notably, at Synthelabo (later acquired by Sanofi-Aventis), Dr. Angel played a pivotal role in advancing several drugs, including Litoxetine for depression and Deriglidole for Type-II diabetes, from conception to Investigational New Drug (IND) applications and clinical trials. Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem).

Beyond his tenure at Synthelabo, Dr. Angel has made significant advancements in the pharmaceutical industry, including impactful work at several companies, such as Teva, where he was an external consultant in strategic drug development and innovation. He has also founded and served as an officer and director of several pharma start-ups. He was Vice President for Research and Development at D-Pharm Biopharmaceuticals, where he advanced DP-VPA into the human trials for epilepsy and bi-polar disorders (later licensed to Shire Pharmaceuticals) and the chelator DP-b99 for stroke (which advanced to phase-III clinical trials). Dr Angel also served as President and Chief Executive Officer of stem-cell company Accellta; Vice President for Research and Development at Proteologics Ltd and at Galmed Pharmaceuticals (where he advanced Aramchol through an IND to phase-II clinical trials); Head of Discovery and Research and Development Center Biopharma (where he advanced Zygosid-50 towards clinical trials) and others. His experience extends through various therapeutic areas and has led to the successful research and development of several drugs, highlighting his vast expertise and ability to bring critical treatments through the regulatory process and ultimately to market.

Dr. Angel's extensive background in drug development, from preclinical research through clinical trials and market introduction, positions him well to contribute to MIRA's scientific endeavors. His leadership is expected to accelerate MIRA's research and development pipeline, particularly in advancing its flagship compounds, including the innovative Ketamir-2 for treatment-resistant depression.

"We are truly honored to have Dr. Angel on our team," stated Erez Aminov, Chairman & CEO of MIRA. "His distinguished career across the pharmaceutical industry, from start-ups to big pharma, his exceptional scientific skills and his dedication to pharmaceutical innovation will help propel our promising pre-clinical drug candidates forward. His expertise will be invaluable as we move our product candidates towards INDs and through the clinical trial and regulatory approval process and also as we seek to expand our product candidate portfolio."

Dr. Angel stated, "I am thrilled to contribute to MIRA's pioneering efforts in addressing the challenges in neurologic and neuropsychiatric disorders. I look forward to applying my experience and insights to help advance MIRA."

Source & Image Credit: [MIRA Pharmaceuticals, Inc.](#)

